{
    "root": "316a5f06-1f9b-7edc-e063-6394a90abbe9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ranolazine",
    "value": "20250328",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "RANOLAZINE",
            "code": "A6IEZ5M406"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "Ranolazine extended-release tablets are indicated for the treatment of chronic angina.\n                  Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.",
    "contraindications": "500 mg twice daily and increase to 1000 mg twice daily, based on clinical symptoms (2.1)",
    "warningsAndPrecautions": "Ranolazine Extended Release Tablets are supplied as film-coated, oblong-shaped, extended-release tablets in the following strengths:\n                  \n                     500 mg tablets are orange, with one side debossed S246 and plain on the other side\n                     1000 mg tablets are yellow, with one side debossed S247 and plain on the other side\n                  \n                  Ranolazine extended-release tablets are available in:\n                  \n                     \n                     \n                        \n                           \n                           \n                              \n                                 Strentgh\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                        \n                        \n                            Unit-of-Use Bottle (60 Tablets)\n                            500 mg\n                            70625-206-01\n                        \n                        \n                            Bottle (500 Tablets)\n                            500 mg\n                            70625-206-02\n                        \n                        \n                            Unit-of-Use Bottle (60 Tablets)\n                            1000 mg\n                            70625-207-01\n                        \n                        \n                            Bottle (500 Tablets)\n                            1000 mg\n                            70625-207-02\n                        \n                     \n                  \n                  Store at 25°C (77°F); with excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]\n                  Bottles of 500 tablets are not for household use.",
    "adverseReactions": "Ranolazine extended-release tablets are contraindicated in patients:\n                  \n                     Taking strong inhibitors of CYP3A \n        \n  \n   [see \n                        Drug Interactions (7.1)\n                        ]\n                     \n                     Taking inducers of CYP3A \n        \n  \n   [see \n                        Drug Interactions (7.1)\n                        ]\n                     \n                     With liver cirrhosis \n        \n  \n   [see \n                        Use in Specific Populations (8.6)\n                        ]"
}